Imfinzi (Durvalumab) for Endometrial Cancer

Overview
Imfinzi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). This treatment combines Imfinzi with carboplatin and paclitaxel as an initial regimen, followed by Imfinzi as a single agent. Eligibility is based on a confirmed diagnosis of dMMR endometrial cancer. Imfinzi is also known by its drug name, durvalumab.

Imfinzi belongs to a class of drugs known as immune checkpoint inhibitors. It works by blocking the programmed death-ligand 1 (PD-L1) pathway, helping the immune system recognize and attack cancer cells more effectively.

How do I take it?
Prescribing information states that Imfinzi is administered as an intravenous (IV) infusion. It is generally combined with carboplatin and paclitaxel every three weeks for six cycles, followed by Imfinzi as a single agent every four weeks. Imfinzi should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Imfinzi include peripheral neuropathy (nerve damage causing pain or weakness), musculoskeletal pain, nausea, alopecia (hair loss), fatigue, abdominal pain, constipation, rash, decreased magnesium, increased liver enzymes (ALT and AST), diarrhea, vomiting, cough, decreased potassium, shortness of breath, headache, increased alkaline phosphatase (a liver enzyme), and decreased appetite.

Rare but serious side effects may include immune-mediated reactions such as pneumonitis (lung inflammation), colitis (intestinal inflammation), hepatitis (liver inflammation), endocrinopathies (hormone gland disorders), nephritis (kidney inflammation), severe skin reactions, infusion-related reactions, and complications with allogeneic stem cell transplants. The medication can also cause harm to an unborn baby when taken during pregnancy.

For more information about this treatment, visit:

Label: Imfinzi — Durvalumab Injection, Solution — DailyMed